Strategies are needed for drafting miRNA patent applications, in light of the existing patent landscape and genomic patent strategies of the past decades.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fire, A. et al. Nature 391, 806–811 (1998).
He, L. & Hannon, G.J. Nat. Rev. Genet. 5, 522–531 (2004).
Townley-Tilson, W.H., Callis, T.E. & Wang, D. Int. J. Biochem. Cell Biol. 42, 1252–1255 (2010).
Zheng, K. et al. J. Neurosci. 30, 8245–8250 (2010).
Jones, C.I. & Newbury, S.F. Biochem. Soc. Trans. 38, 1137–1143 (2010).
Letzen, B.S. et al. PLoS ONE 5, e10480 (2010).
Almanza, G. et al. PLoS ONE 5, e11243 (2010).
Yu, Z. et al. Am. J. Pathol. 176, 1058–1064 (2010).
Cho, W.C. Biochim. Biophys. Acta 1805, 209–217 (2010).
Hime, G.R. & Somers, W.G. Cell Adh. Migr. 3, 425–432 (2009).
Weber, M., Baker, M.B., Moore, J.P. & Searles, C.D. Biochem. Biophys. Res. Commun. 393, 643–648 (2010).
Elia, L. et al. Cell Death Differ. 16, 1590–1598 (2009).
Huang, Z.P., Neppl, R.L. & Wang, D.Z. J. Cardiovasc. Transl. Res. 3, 212–218 (2010).
Adams, B.D., Furneaux, H. & White, B.A. Mol. Endocrinol. 21, 1132–1147 (2007).
Sullivan, C.S. & Ganem, D. Mol. Cell 20, 3–7 (2005).
Lecellier, C.-H. et al. Science 308, 557–560 (2005).
Taganov, K.D., Boldin, M.P., Chang, K.-J. & Baltimore, D. Proc. Natl. Acad. Sci. USA 103, 12481–12486 (2006).
Taganov, K.D., Boldin, M.P. & Baltimore, D. Immunity 26, 133–137 (2007).
Davis, P., Kelley, J.J., Caltrider, S.P. & Heinig, S.J. Nat. Biotechnol. 23, 1227–1229 (2005).
US 11/747,409, Office Action dated February 13, 2009.
US 11/747,409, Reply to Office Action dated August 3, 2009; Cf. In re Fisher, 421 F.3d 1365, 1376 (Fed. Cir. 2005).
EP 02782801, Examiner's Report dated July 28, 2009.
Id.
<http://www.alnylam.com/Business-Development/Academic-Federal-and-Foundation-Collaborations.php>
12/550,602, issued as US Patent No. 7,838,663 on November 23, 2010 (claims directed to miRNA-125a and 125b sequences); 12/550,586, issued as US Patent No. 7,838,661 on November 23, 2010 (claims directed to miRNA-124 sequences); 12/550, 704, issued as US Patent No. 7,838,664 on November 23, 2010 (claims directed to miRNA-142 sequences); 12/550,596, issued as US Patent No. 7,838,662 on November 23, 2010 (claims directed to miRNA-15a, 15b and 16 sequences); 12/550,579, issued as US Patent No. 7,838,660 on November 23, 2010 (claims directed to miRNA155 sequences).
35 USC §101.
Manual of Patent Examining Procedure §2107; “Utility Examination Guidelines,” Fed. Regist. 66, 1092–1099 (2001).
Manual of Patent Examining Procedure §2107.01; see also Fisher, 421 F.3d at 1376 (Fed. Cir. 2005).
Manual of Patent Examining Procedure §2107.01.
Davis, et al. at n. 19; see also Overview of Comments in “Utility Examination Guidelines”. Fed. Regist. 66, 1092–1099 (2001).
Reynolds, T. J. Natl. Cancer Inst. 92, 96–97 (2000).
Manual of Patent Examining Procedure §2107.01(I)(A).
In re: Kirk, 376 F.2d 936 (CCPA 1967).
Reynolds at n. 30.
Manual of Patent Examining Procedure §2107.01(I)(B).
Nelson v. Bowler, 626 F.2d 853 (CCPA 1980).
MPEP at n. 34.
Manual of Patent Examining Procedure §2107.02(III)(B).
Id.
Rasmusson v. SmithKline Beecham Corp., 75 USPQ 1297, 1300 (Fed. Cir. 2005), quoting Envirotech Corp. v. Al George, Inc., 221 USPQ 473 (Fed. Cir. 1984).
Rasmusson, at 1300.
421 F.3d 1365 (Fed. Cir. 2005).
d. at 1374.
Id.
421 F. 3d 1376.
Storella, J. A Bioinformatics Business Model and the Bold Strategy Behind It: The Case of Incyte Genomics, The American Conference Institute, 5th Advanced Forum on Biotech Patents (Sept. 2005). <http://www.wsgr.com/attorneys/NEWBIOS/PDFs/storella0905.pdf>
Schultz, J.D. Patenting Interfering RNA, SPE Art Unit 1635, USPTO (date unknown). <http://www.cabic.com/bcp/061307/JSchultz_PIRNA.ppt>
Smalheiser, N.R. & Torvil, V.I. in MicroRNA Protocols (ed. Ying, S.-Y.) 115–127 (Humana Press, 2006).
Rasmusson at n. 40.
Maragkakis, M. et al. BMC Bioinformatics 10, 295–304 (2009).
Kunin, S.G., Nagumo, M., Stanton, B., Therkorn, L.S. & Walsh, S. Am. Univ. Law Rev. 51, 609–638 (2002).
35 USC §112 (2001).
Kunin et al. at n. 50.
Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1563–64 (Fed. Cir. 1991).
US 10/909,125, Notice of Allowability dated October 22, 2009.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
MiRagen, a company active in the microRNA space, is a Cooley patent prosecution client; and B.V.M. and E.V. previously represented the Carnegie Institution of Washington for the Andrew Fire/Craig Mello portfolio directed to RNAi.
Rights and permissions
About this article
Cite this article
McLeod, B., Hayman, M., Purcell, A. et al. The 'real world' utility of miRNA patents: lessons learned from expressed sequence tags. Nat Biotechnol 29, 129–133 (2011). https://doi.org/10.1038/nbt.1765
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1765
This article is cited by
-
Therapeutic microRNAs in human cancer
Cytotechnology (2019)
-
Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression
Molecular Psychiatry (2012)
-
Is silence still golden? Mapping the RNAi patent landscape
Nature Biotechnology (2011)